Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors. - Shi Y; McKenery A; Dolan M; Mastri M; Hill JW; Dommer A; Benzekry S; Long M; Abrams SI; Puzanov I; Ebos JML (EMBO reports, 2025)